Association Between Vitamin D Receptor Polymorphism and the Response to Helicobacter Pylori Treatment

• Published in: Infection and drug resistance Vol. 16; pp. 4463 - 4469
• Main Authors: Abo-Amer, Yousry Esam-Eldin, Mohamed, Amal Ahmed, Elhoseeny, Mohamed Mahmoud, Rezk, Samar M, Abdel-Salam, Sherief, Alrohaimi, Abdulmohsen H, Abdelgeliel, Asmaa Sayed, Alzahrani, Seham Saeed, Jafri, Ibrahim, Alqahtani, Leena S, Fayad, Eman, Fakhry, Mohamed, Soliman, Moataz Yousry
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2023; Dove; Dove Medical Press
• Subjects: Alfacalcidol; Amoxicillin; Calcifediol; eradication; gene; Genes; Genetic aspects; Genetic polymorphisms; Health aspects; helicobacter; Helicobacter infections; Helicobacter pylori; Infection; Medical research; Medicine, Experimental; Omeprazole; Original Research; polymorphism; response; Vitamin D; Egypt; infection; polymorphism; Helicobacter; gene; eradication; response
• ISSN: 1178-6973; 1178-6973
• DOI: 10.2147/IDR.S414186

This research aimed to determine how variations in the vitamin D receptor gene affected the response of infections to eradication therapy. On 105 adult -positive patients, a prospective cohort study was carried out. PCR was used to genotype all patients' VDR gene polymorphisms. The patients in the study received standard triple eradication medication (clarithromycin 500 mg, amoxicillin 1000 mg, and omeprazole 20 mg) twice daily for 14 days. A stool test for Ag was conducted 4 weeks following the end of treatment. In our study, the usual triple therapy's eradication rate was 75.2%. The successful eradication of H. pylori and VDR rs 2228570 gene polymorphisms was more prevalent in CT gene polymorphism (64.6%) compared to non-responders (19.2%), while treatment failure was more prevalent in CC gene polymorphism (73.1% in non-responders compared to responders 24.1%), which is statistically significant. In regards to the eradication of and VDR rs7975232 gene polymorphisms, the success of eradication was more prevalent in AC gene polymorphism (54.4%) vs non-responders (30.4%), while all patients (14) with gene AA (17.7%) are responders to standard treatment, while the failure of treatment was more prevalent in CC gene polymorphism (69.2% in non-responder vs 27.8% in responders) which is statistically significant. Our findings demonstrated a strong correlation between patients' responses to treatment and polymorphisms in the VDR gene (ApaI and TaqI) (P 0.05). As far as we are aware, this is the first study to identify a potential link between the FokI and Apal VDR polymorphism and treatment response in -positive patients. To evaluate the findings, more research with larger number of patients and different population is required.